Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Reduced lung-cancer mortality with low-dose computed tomographic screening.

National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD.

N Engl J Med. 2011 Aug 4;365(5):395-409. doi: 10.1056/NEJMoa1102873. Epub 2011 Jun 29.

2.

An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study.

Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK, Horgan PG, McMillan DC.

Br J Cancer. 2011 Feb 15;104(4):726-34. doi: 10.1038/sj.bjc.6606087. Epub 2011 Jan 25.

3.

Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.

Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, Miller YE, Pass HI, Rom WN, Siegfried JM, Stewart A, Walker JJ, Weissfeld JL, Williams S, Zichi D, Brody EN.

PLoS One. 2010 Dec 7;5(12):e15003. doi: 10.1371/journal.pone.0015003.

4.

Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients.

Andersen JD, Boylan KL, Jemmerson R, Geller MA, Misemer B, Harrington KM, Weivoda S, Witthuhn BA, Argenta P, Vogel RI, Skubitz AP.

J Ovarian Res. 2010 Sep 10;3:21. doi: 10.1186/1757-2215-3-21.

5.

The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study.

Proctor MJ, Talwar D, Balmar SM, O'Reilly DS, Foulis AK, Horgan PG, Morrison DS, McMillan DC.

Br J Cancer. 2010 Sep 7;103(6):870-6. doi: 10.1038/sj.bjc.6605855. Epub 2010 Aug 17.

6.

Complement factor H autoantibodies are associated with early stage NSCLC.

Amornsiripanitch N, Hong S, Campa MJ, Frank MM, Gottlin EB, Patz EF Jr.

Clin Cancer Res. 2010 Jun 15;16(12):3226-31. doi: 10.1158/1078-0432.CCR-10-0321. Epub 2010 Jun 1.

7.

Antigen identification and characterization of lung cancer specific monoclonal antibodies produced by mAb proteomics.

Wang D, Hincapie M, Guergova-Kuras M, Kadas J, Takacs L, Karger BL.

J Proteome Res. 2010 Apr 5;9(4):1834-42. doi: 10.1021/pr900997z.

8.

N-glycosylation status of beta-haptoglobin in sera of patients with prostate cancer vs. benign prostate diseases.

Yoon SJ, Park SY, Pang PC, Gallagher J, Gottesman JE, Dell A, Kim JH, Hakomori SI.

Int J Oncol. 2010 Jan;36(1):193-203.

9.

Management of lung nodules detected by volume CT scanning.

van Klaveren RJ, Oudkerk M, Prokop M, Scholten ET, Nackaerts K, Vernhout R, van Iersel CA, van den Bergh KA, van 't Westeinde S, van der Aalst C, Thunnissen E, Xu DM, Wang Y, Zhao Y, Gietema HA, de Hoop BJ, Groen HJ, de Bock GH, van Ooijen P, Weenink C, Verschakelen J, Lammers JW, Timens W, Willebrand D, Vink A, Mali W, de Koning HJ.

N Engl J Med. 2009 Dec 3;361(23):2221-9. doi: 10.1056/NEJMoa0906085.

10.
11.

Expression of the acute phase protein haptoglobin in human lung cancer and tumor-free lung tissues.

Abdullah M, Schultz H, Kähler D, Branscheid D, Dalhoff K, Zabel P, Vollmer E, Goldmann T.

Pathol Res Pract. 2009;205(9):639-47. doi: 10.1016/j.prp.2009.04.007. Epub 2009 Jun 7.

PMID:
19501987
12.

Mass spectrometry-based proteomic profiling of lung cancer.

Ocak S, Chaurand P, Massion PP.

Proc Am Thorac Soc. 2009 Apr 15;6(2):159-70. doi: 10.1513/pats.200809-108LC. Review.

13.

Up-regulation of the expression of leucine-rich alpha(2)-glycoprotein in hepatocytes by the mediators of acute-phase response.

Shirai R, Hirano F, Ohkura N, Ikeda K, Inoue S.

Biochem Biophys Res Commun. 2009 May 15;382(4):776-9. doi: 10.1016/j.bbrc.2009.03.104. Epub 2009 Mar 24.

PMID:
19324010
14.

Altered glycosylation in tumours focused to cancer diagnosis.

Peracaula R, Barrabés S, Sarrats A, Rudd PM, de Llorens R.

Dis Markers. 2008;25(4-5):207-18. Review.

15.

Biomarker studies abound for early detection of lung cancer.

Brower V.

J Natl Cancer Inst. 2009 Jan 7;101(1):11-3. doi: 10.1093/jnci/djn483. Epub 2008 Dec 30. No abstract available.

PMID:
19116384
16.

Clinical impact of high-throughput gene expression studies in lung cancer.

Beane J, Spira A, Lenburg ME.

J Thorac Oncol. 2009 Jan;4(1):109-18. doi: 10.1097/JTO.0b013e31819151f8. Review.

17.

Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking.

Kiri VA, Fabbri LM, Davis KJ, Soriano JB.

Respir Med. 2009 Jan;103(1):85-90. doi: 10.1016/j.rmed.2008.07.024. Epub 2008 Sep 14.

18.

Differentially expressed serum haptoglobin alpha chain isoforms with potential application for diagnosis of head and neck cancer.

Chen CB, Su YC, Huang TT, Ho HC, Chang YT, Tung YT, Lee WC.

Clin Chim Acta. 2008 Dec;398(1-2):48-52. doi: 10.1016/j.cca.2008.08.001. Epub 2008 Aug 7.

PMID:
18727923
19.

Preparation of a high-performance multi-lectin affinity chromatography (HP-M-LAC) adsorbent for the analysis of human plasma glycoproteins.

Kullolli M, Hancock WS, Hincapie M.

J Sep Sci. 2008 Aug;31(14):2733-9. doi: 10.1002/jssc.200800233.

PMID:
18693314
20.

ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand.

Weivoda S, Andersen JD, Skogen A, Schlievert PM, Fontana D, Schacker T, Tuite P, Dubinsky JM, Jemmerson R.

J Immunol Methods. 2008 Jul 20;336(1):22-9. doi: 10.1016/j.jim.2008.03.004. Epub 2008 Apr 4.

PMID:
18436231

Supplemental Content

Support Center